Sign inCreate account

Report workspace tools

NCT03461146COMPLETEDanonymous

A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Sponsor

Source record

Tanabe Pharma Corporation

Phase

Source record

Phase III

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia associated with chronic kidney disease in hemodialysis subjects

Indication / condition

AI-normalized

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Intervention

Source record

MT-6548

Source & freshness

Source record

NCT ID

NCT03461146

Original source

ClinicalTrials.gov

Source last updated

Apr 06, 2026

Ingested at

Jun 03, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03461146

Title

A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Sponsor

Tanabe Pharma Corporation

Status

COMPLETED

Phase

Phase III

Condition raw

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Condition normalized

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Modality raw

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Modality normalized

small molecule

Target raw

Anemia associated with chronic kidney disease in hemodialysis subjects

Target normalized

Anemia associated with chronic kidney disease in hemodialysis subjects

Interventions

MT-6548

Public preview

Source record

Tanabe Pharma Corporation conducted a Phase III trial of MT-6548, an oral tablet, to evaluate its efficacy and safety in hemodialysis patients with anemia not receiving erythropoiesis-stimulating agents (ESAs). The study enrolled 24 participants and aimed to assess hemoglobin (Hb) correction and maintenance.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03461146

Status

COMPLETED

Phase

Phase III

Sponsor

Tanabe Pharma Corporation

Executive brief

Investment-Ready Snapshot

Tanabe Pharma Corporation conducted a Phase III trial of MT-6548, an oral tablet, to evaluate its efficacy and safety in hemodialysis patients with anemia not receiving erythropoiesis-stimulating agents (ESAs). The study enrolled 24 participants and aimed to assess hemoglobin (Hb) correction and maintenance.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 06, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03461146

Indication

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Modality

small molecule

Target

Anemia associated with chronic kidney disease in hemodialysis subjects

Intervention

MT-6548

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.